| Texto completo | |
| Autor(es): |
Calvo, Adriana Maria
;
Santos, Gabriel Mulinari
;
Dionisio, Thiago Jose
;
Marques, Maria Paula
;
Brozoski, Daniel Thomas
;
Lanchote, Vera Lucia
;
Raposo Fernandes, Maria Helena
;
Cardoso Faria, Flavio Augusto
;
Santos, Carlos Ferreira
Número total de Autores: 9
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Journal of Pharmaceutical and Biomedical Analysis; v. 120, p. 9-pg., 2016-02-20. |
| Resumo | |
Saliva sampling used to quantify piroxicam and 5'-hydroxypiroxicam is a noninvasive and painless method when compared to sequential blood sampling. For that, a rapid, selective and sensitive liquid chromatography-tandem mass spectrometric method for simultaneous determination of piroxicam and 5'-hydroxypiroxicam in saliva and human plasma was developed and validated. Piroxicam and its major metabolite were separated using a LiChroCART 125-4 RP Select-B Sorbent C18 column using a mixture of methanol and 2% phosphoric acid (pH 2.7) (70:30, v/v) for the mobile phase with a flow injection of 1 mL/min. The run time was 4 min. Volunteers had saliva and blood sampled before, 1, 2, 3, 4, 5, 6, 8, 11, 24, 48 and 72 h after taking a 20 mg oral dose of piroxicam. The pharmacokinetic parameters of piroxicam in plasma samples were as follows: AUC(0-72) (64819 h ng/mL), predicted clearance (0.2 L/h), distribution volume (14.8 L), elimination half-life (50.7 h) and saliva/plasma concentration ratio (0.003). The"estimation of all pharmacokinetic parameters for 5'-hydroxypiroxicam would require collections beyond 72 h; however, it was possible to quantify the mean maximum concentration (133 ng/mL), time to peak concentration (53.6 h), mean AUC(0-72) (6213 h ng/mL), predicted clearance (110.31.1h) and saliva/plasma concentration ratio (0.04). The developed methods proved effective and sensitive for determining the lower quantification limit of piroxicam in plasma (6.1 ng/mL) and saliva (0.15 ng/mL) and of 5'-hydroxypiroxicam in plasma (1.2 ng/mL) and saliva (0.15 ng/mL). (C) 2015 Elsevier B.V. All rights reserved. (AU) | |
| Processo FAPESP: | 14/17803-1 - Influência do genótipo do Citocromo P450 (CYP2C9) na eficácia clínica e farmacocinética do Piroxicam após cirurgias de terceiros molares inferiores |
| Beneficiário: | Carlos Ferreira dos Santos |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 09/17851-8 - Influência do genótipo do citocromo P450 (CYP2C9) na eficácia clínica e farmacocinética do piroxicam após cirurgias de terceiros molares inferiores |
| Beneficiário: | Adriana Maria Calvo |
| Modalidade de apoio: | Bolsas no Brasil - Pós-Doutorado |
| Processo FAPESP: | 15/10198-8 - Estudo da farmacogenética do citocromo P450 e farmacocinética do piroxicam em amostras de saliva através de espectrometria de massas. |
| Beneficiário: | Gabriel Mulinari dos Santos |
| Modalidade de apoio: | Bolsas no Brasil - Iniciação Científica |